$141,656,003
to LEIDOS BIOMEDICAL RESEARCH INC
ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2)
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Latest obligation on a 2021 NIH contract funding development of a universal flu vaccine (FluMosV2) through 2031.
Universal influenza vaccines could reduce pandemic risk and eliminate annual flu shot reformulation, addressing a decades-long public health goal.
Leidos Biomedical leads manufacturing and clinical development; success requires upstream viral vector suppliers, adjuvant manufacturers, and downstream clinical trial infrastructure.
Vaccine platform leadership is strategically important; China is pursuing universal flu vaccines in parallel, making U.S. speed-to-market critical.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-24. Cost: $0.002975.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75N91021F00004_7529_75N91019D00024_7529.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.